HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial | Zendy

William C. Knowler | Zendy; Sharon L. Edelstein | Zendy; Ronald Goldberg | Zendy; Ronald T. Ackermann | Zendy; Jill P. Crandall | Zendy; José C. Florez | Zendy; Sarah Fowler | Zendy; William H. Herman | Zendy; Edward S. Horton | Zendy; Steven E. Kahn | Zendy; Kieren J. Mather | Zendy; David M. Nathan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial

Author(s) -

William C. Knowler,

Sharon L. Edelstein,

Ronald Goldberg,

Ronald T. Ackermann,

Jill P. Crandall,

José C. Florez,

Sarah Fowler,

William H. Herman,

Edward S. Horton,

Steven E. Kahn,

Kieren J. Mather,

David M. Nathan

Publication year - 2014

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-0886

Subject(s) - medicine , diabetes mellitus , metformin , glycated hemoglobin , type 2 diabetes , randomized controlled trial , research design , placebo , endocrinology , social science , alternative medicine , pathology , sociology

Glycated hemoglobin (HbA1c), a standard measure of chronic glycemia for managing diabetes, has been proposed to diagnose diabetes and identify people at risk. The Diabetes Prevention Program (DPP) was a 3.2-year randomized clinical trial of preventing type 2 diabetes with a 10-year follow-up study, the DPP Outcomes Study (DPPOS). We evaluated baseline HbA1c as a predictor of diabetes and determined the effects of treatments on diabetes defined by an HbA1c ≥6.5% (48 mmol/mol).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research